End-of-day quote
Korea S.E.
18:00:00 2024-05-13 EDT
|
5-day change
|
1st Jan Change
|
6,410
KRW
|
-0.16%
|
|
+0.94%
|
-3.03%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
269,932
|
187,532
|
310,369
|
313,540
|
213,543
|
179,354
|
Enterprise Value (EV)
1 |
187,050
|
120,470
|
250,784
|
267,826
|
195,284
|
162,653
|
P/E ratio
|
51.4
x
|
9.32
x
|
22.1
x
|
24.9
x
|
17.6
x
|
-8.66
x
|
Yield
|
2.63%
|
5.05%
|
4.46%
|
4.37%
|
5.08%
|
6.05%
|
Capitalization / Revenue
|
1.51
x
|
1.06
x
|
1.79
x
|
1.77
x
|
1.17
x
|
1.1
x
|
EV / Revenue
|
1.04
x
|
0.68
x
|
1.44
x
|
1.51
x
|
1.07
x
|
1
x
|
EV / EBITDA
|
6.88
x
|
3.87
x
|
9.75
x
|
11.8
x
|
13
x
|
-8.51
x
|
EV / FCF
|
4.97
x
|
-61
x
|
-31
x
|
41.9
x
|
-70.4
x
|
319
x
|
FCF Yield
|
20.1%
|
-1.64%
|
-3.22%
|
2.39%
|
-1.42%
|
0.31%
|
Price to Book
|
1.27
x
|
0.83
x
|
1.18
x
|
1.2
x
|
0.83
x
|
0.79
x
|
Nbr of stocks (in thousands)
|
23,678
|
23,678
|
27,712
|
27,383
|
27,134
|
27,134
|
Reference price
2 |
11,400
|
7,920
|
11,200
|
11,450
|
7,870
|
6,610
|
Announcement Date
|
3/11/19
|
3/13/20
|
3/19/21
|
3/21/22
|
3/22/23
|
3/21/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
179,316
|
176,500
|
173,828
|
177,611
|
182,718
|
162,674
|
EBITDA
1 |
27,193
|
31,121
|
25,724
|
22,770
|
15,016
|
-19,106
|
EBIT
1 |
20,385
|
24,155
|
18,950
|
15,758
|
8,312
|
-24,955
|
Operating Margin
|
11.37%
|
13.69%
|
10.9%
|
8.87%
|
4.55%
|
-15.34%
|
Earnings before Tax (EBT)
1 |
20,233
|
34,945
|
19,339
|
18,432
|
17,941
|
-18,503
|
Net income
1 |
5,242
|
20,126
|
12,459
|
12,672
|
12,161
|
-20,708
|
Net margin
|
2.92%
|
11.4%
|
7.17%
|
7.13%
|
6.66%
|
-12.73%
|
EPS
2 |
221.8
|
850.0
|
507.8
|
460.4
|
447.0
|
-763.2
|
Free Cash Flow
1 |
37,643
|
-1,973
|
-8,079
|
6,388
|
-2,773
|
510.2
|
FCF margin
|
20.99%
|
-1.12%
|
-4.65%
|
3.6%
|
-1.52%
|
0.31%
|
FCF Conversion (EBITDA)
|
138.43%
|
-
|
-
|
28.05%
|
-
|
-
|
FCF Conversion (Net income)
|
718.08%
|
-
|
-
|
50.41%
|
-
|
-
|
Dividend per Share
2 |
300.0
|
400.0
|
500.0
|
500.0
|
400.0
|
400.0
|
Announcement Date
|
3/11/19
|
3/13/20
|
3/19/21
|
3/21/22
|
3/22/23
|
3/21/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
82,882
|
67,062
|
59,585
|
45,714
|
18,259
|
16,701
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
37,643
|
-1,973
|
-8,079
|
6,388
|
-2,773
|
510
|
ROE (net income / shareholders' equity)
|
2.43%
|
10.1%
|
5.17%
|
4.83%
|
4.68%
|
-8.53%
|
ROA (Net income/ Total Assets)
|
5%
|
5.54%
|
4.09%
|
3.38%
|
1.72%
|
-5.17%
|
Assets
1 |
104,760
|
363,522
|
304,536
|
375,288
|
705,159
|
400,603
|
Book Value Per Share
2 |
8,941
|
9,574
|
9,461
|
9,540
|
9,479
|
8,409
|
Cash Flow per Share
2 |
1,272
|
2,659
|
577.0
|
654.0
|
536.0
|
434.0
|
Capex
1 |
3,931
|
2,055
|
28,591
|
3,926
|
10,574
|
6,290
|
Capex / Sales
|
2.19%
|
1.16%
|
16.45%
|
2.21%
|
5.79%
|
3.87%
|
Announcement Date
|
3/11/19
|
3/13/20
|
3/19/21
|
3/21/22
|
3/22/23
|
3/21/24
|
|
1st Jan change
|
Capi.
|
---|
| -3.03% | 129M | | +21.98% | 43.92B | | +24.56% | 23.09B | | +18.99% | 15.35B | | +14.03% | 13.61B | | +46.40% | 12.02B | | -10.14% | 7B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.07% | 5.6B |
Generic Pharmaceuticals
|